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Pancreatic stone protein/regenerating protein I𝛼 (PSP/REG I𝛼) is a secretory protein produced in the pancreas, but its expression
has also been observed in the kidney. It may be associated with kidney dysfunction.This study investigates the possible association
between PSP/REG I𝛼 and kidney function in pregnant women. Serum PSP/REG I𝛼 levels were measured by a specific ELISA
enzyme-linked immunosorbent assay. Maternal information and clinical and biochemical parameters were collected. Estimated
glomerular filtration rate (eGFR) was calculated for all individuals to evaluate their renal function. Spearman’s correlation and
multiple linear regression analyses were performed to assess the associations between PSP/REG I𝛼 and eGFR, serum creatinine
(Cr), blood urea nitrogen (BUN), and uric acid (UA). A total of 595 pregnant women were enrolled in the study. Participants with
mildly reduced eGFR had higher PSP/REG I𝛼 levels [50.49 (35.02, 58.64)] than in the general population [26.84 (21.02, 33.07)] (p <
0.001). Included participants were stratified into PSP/REG I𝛼 quartiles; significant differences were observed in the levels of eGFR,
serum Cr, BUN, and UA. PSP/REG I𝛼 was negatively correlated with eGFR (r = −0.402, p < 0.001) and positively associated with
serum Cr (r = 0.468, p < 0.001), BUN (r = 0.166, p < 0.001), and UA (r = 0.207, p < 0.001). The linear regression analysis indicated
that PSP/REG I𝛼 was associated with UA, BUN, and eGFR. High PSP/REG I𝛼 concentrations were closely associated with renal
dysfunction in pregnant women. Our study provides clinical evidence that serum PSP/REG I𝛼 levels could be a novel biomarker
for assessment of renal function in pregnant women.
1. Introduction
Chronic kidney disease (CKD) is a global public health
concern because of its increasing incidence and prevalence.
The prevalence of CKD is approximately 3% in women of
childbearing age. Few studies investigated kidney disease
during pregnancy [1, 2]. Women with renal disease are at
a greater risk for maternal and fetal complications, includ-
ing miscarriage, preterm delivery, preeclampsia, and fetal
hypotrophy [3–5]. Moreover, pregnant women with a mild
increase in glomerular filtration rate (GFR) possess a higher
risk of adverse events than thosewithout kidney disease [1, 6].
Although serum creatinine is a most important predictor for
outcomes of pregnancy in CKD women, it is insensitive to
mild and moderate renal impairment [7, 8]. Additionally,
estimated GFR (eGFR) may likewise be unreliable in certain
populations [9]. Given the scarcity of adequately sensitive
and specific markers of kidney function in pregnant women,
sensitive indicators should be identified to optimize clinical
practice.
Regenerating (REG) family proteins are structurally sim-
ilar proteins belonging to the calcium-dependent (C-type)
lectin superfamily. In humans, REG family has five functional
proteins, REG I𝛼, REG I𝛽, HIP/PAP, REG III, and REG IV.
Pancreatic stone protein (PSP) is a product of REG I𝛼 gene;
sequence comparison later revealed that REG I𝛼 andPSPpro-
teins are identical [10]. Pancreatic stone protein/regenerating
I𝛼 (PSP/REG I𝛼) was originally identified as a 16 kDa
polypeptide in pancreatic stones [10]. It has been studied
mainly in the pancreas and was prominently upregulated in
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acute or chronic pancreatitis [11]. In addition, it appeared
to promote regeneration of islets by induction of cellular
proliferation [12]. PSP/REG I𝛼 was also found in the urine
and renal calculi of healthy individuals [13, 14], suggesting
a physiological role of PSP/REG I𝛼 in the kidney. Sobajima
et al. [15] reported that urinary PSP/REG I𝛼 was markedly
elevated in patients with various renal diseases, including
diabetic nephropathy. Our previous studies have accumu-
lated compelling evidence for elevated PSP/REG I𝛼 levels
in patients with chronic diabetic complications and diabetic
kidney disease [16, 17]. Nevertheless, limited information is
available regarding the association between serum PSP/REG
I𝛼 and renal function in pregnant women. Identification of
such a serologic marker may provide new approaches for the
prevention of progressive renal insufficiency in pregnancy.
Therefore, we aimed to investigate the association between
serum PSP/REG I𝛼 levels and renal function in pregnant
women.
2. Materials and Methods
2.1. Study Subjects. This cross-sectional study of 595 pregnant
women was conducted at the Zhongda Hospital Affiliated
with Southeast University in Nanjing, China. The study was
approved by the hospital ethics committee (2016ZDSYLL076-
P01), and experimental methods were performed strictly in
accordance with the approved guidelines. Written informed
consent was obtained from all participants.
Pregnant women were recruited before their delivery
from March 2016 to December 2017. Pregnant women aged
20–55 years were included in the study.The exclusion criteria
included the following: maternal age of less than 20 years
and more than 55 years, diagnosis of pregestational diabetes,
autoimmune diseases prior to pregnancy, prepregnancy car-
diovascular diseases, and severe hepatic disorders before
pregnancy.
2.2. Data Collection and Quality Assessment. We collected
information on demographics, maternal age, education and
employment, pregestational weight and height, last men-
struation, pregnancy and obstetrical history, hypertension,
and macrosomia in previous pregnancies. From each preg-
nant woman, 5ml of peripheral blood was collected and
centrifuged directly for 6min at 3,000 g. The obtained
serum was immediately frozen in sterile tubes at −80∘C.
Other clinical biochemical parameters, such as fasting blood
glucose (FBG), total cholesterol, triglyceride, low-density
lipoprotein, high-density lipoprotein, Cr, uric acid (UA),
and blood urea nitrogen (BUN), were measured using the
standard methods. The Laboratory Center of Zhongda Hos-
pital conducts internal and external quality control proce-
dures directed by the Chinese Laboratory Quality Control.
Body mass index (BMI) was calculated using the follow-
ing formula: BMI = body weight (kg)/body height (m2).
eGFR was calculated using the modified CKD Epidemi-
ology Collaboration (CKD-EPI) equation for Asians [18].
The following formula was used: GFR (ml/min/1.73m2)
= 141 × min (SCr/0.7, 1)−0.329 × max (SCr /0.7, 1)−1.209 ×
0.993age × 1.018. Kidney function was classified, using the
method proposed by the National Kidney Foundation, into
three categories: normal (eGFR ≥ 90ml/min/1.73m2), mildly
reduced (eGFR = 60ml/min/1.73m2 to 89ml/min/1.73m2),
andmoderately–severely reduced (eGFR= 15ml/min/1.73m2
to 59ml/min/1.73m2) [8].
2.3. PSP/REG I𝛼 Enzyme–Linked Immunosorbent Assay
(ELISA). PSP/REG I𝛼 level was determined using an iso-
form specific ELISA, as previously described [19]. The
serum collected from patients was incubated in plates pre-
coated with guinea pig anti-human recombinant PSP/REG
I𝛼 antibody. Rabbit anti-human PSP/REG I𝛼 was added
to the plate which was then subjected to detection with
phosphatase–conjugated anti-rabbit immunoglobulin G.The
detection limit was < 0.1 ng/ml, and the interplate variance
was < 10%. The antibodies used in this assay are specific
for human PSP/REG I𝛼 with no known cross reactivities to
recombinant human REG proteins. The PSP/REG I𝛼 ELISA
is covered by a patent governed by international law.
2.4. Statistical Analysis. Statistical analyses were performed
by SPSS 19.0 software. Continuous variables were indicated
as means ± SDs if the continuous variables followed normal
distribution. Nonnormally distributed values were presented
as median (interquartile range [IQR]). Significant differences
were assessed by either the Wilcoxon–Mann–Whitney test
or one-way ANOVA. Correlations between PSP/REG I𝛼
and clinical parameters were determined using Pearson’s
correlation analysis or Spearman’s rank correlation coeffi-
cient, whichever was appropriate. Multiple linear regression
analysis was also performed to assess the potential association
between PSP/REG I𝛼, as dependent variable, and the value
of each kidney function indicator by entering age, BMI, and
FBG, as independent variables in the model. All tests were
two-sided, and values at p < 0.05 were considered statistically
significant.
3. Results
3.1. Description of the Study Population. All of the initial 597
participants were subjected to PSP/REG I𝛼 measurement,
and about 595 of them were analyzed for serum Cr, BUN,
and UA. Finally, 595 pregnant women were included in the
study. Analysis with theCKD-EPI equation indicated that 583
participants (97.98%) had normal eGFR and 12 participants
(2.02%) had mildly reduced eGFR. In the total population,
the median (IQR) concentration of PSP/REG I𝛼 was 26.95
(21.24–33.28) ng/ml, and the participantswithmildly reduced
eGFR had higher PSP/REG I𝛼 levels [50.49 (35.02, 58.64)
ng/ml] than in the general population [26.84 (21.02, 33.07)
ng/ml]. Subsequently, the study population was stratified
into PSP/REG I𝛼 quartiles (Table 1). Pregnant women in
quartile IV showed significantly a higher probability of being
nullipara of the four groups (p< 0.05).Thedistribution values
of serum Cr, eGFR, BUN, and UA showed significant differ-
ences among the quartiles. Moreover, the eGFR significantly
decreased from the bottom to the top quartile of PSP/REG I𝛼.
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Figure 1: Relationships of serum PSP/REG I𝛼 levels with kidney function in pregnancy women. (a) Correlation of PSP/REG I𝛼 with blood
urea nitrogen (r = 0.166, p < 0.001). (b) Correlation of PSP/REG I𝛼 with serum uric acid (r = 0.207, p < 0.001). (c) Correlation of PSP/REG
I𝛼 with creatinine (r = 0.468, p < 0.001). (d) Correlation of PSP/REG I𝛼 with eGFR (r = -0.402, p < 0.001).
The median values of serum Cr, BUN, and UA significantly
increased among the PSP/REG I𝛼 categories. No significant
differences were observed in the value distribution of the
other parameters.
3.2. Relationships of PSP/REG I𝛼 Levels to Kidney Function
Indicators in Pregnant Women. Considering the significant
differences in the value distribution of kidney function
indicators, we analyzed their correlation with PSP/REG I𝛼.
Spearman’s correlation analysis showed that serum PSP/REG
I𝛼 levels were negatively correlated with eGFR (r = −0.402; p
< 0.001) and positively associated with serum Cr (r = 0.468,
p = 0.001), BUN (r = 0.166, p < 0.001), and UA (r = 0.207, p <
0.001) (Figure 1). In addition, a partial correlation was found
between PSP/REG I𝛼 level and eGFR after adjusting for UA
and BUN levels. A moderate correlation was also observed
between PSP/REG I𝛼 and eGFR (r = −0.330, p < 0.001).
To further investigate the correlation between PSP/REG
I𝛼 and renal function indicators, we performed subgroup
analysis according to PSP/REG I𝛼 quartiles. PSP/REG I𝛼was
moderately correlated with Cr in quartiles III (r = 0.237, p
= 0.004) and IV (r = 0.412, p = 0.009) and with eGFR in
quartiles III (r = −0.213, p < 0.001) and IV (r = −0.355, p <
0.001) (Table 2).
3.3. Multiple Linear Regression Model. Age, BMI, FBG, UA,
BUN, and eGFR were used in the multiple regression equa-
tion. In this model, UA (𝛽 = 0.022, p = 0.001), BUN (𝛽 =
1.040, p = 0.036), and eGFR (𝛽 = -0.288, p < 0.001) were
all independent predictors of PSP/REG I𝛼. Participants with
elevated UA and BUN and decreased eGFR would have
higher PSP/REG I𝛼 concentrations (Table 3).
4. Discussion
Thepresent study analyzed associations between PSP/REG I𝛼
and renal function in a cross-sectional study of 595 pregnant
women. To date, such associations have not been clearly
understood. We revealed that high PSP/REG I𝛼 concentra-
tions exhibit moderate association with unfavourable renal
function in pregnant women. This study provides clinical
evidence that serum PSP/REG I𝛼 level may be a suitable
marker for assessment of renal function in pregnant women.
Studies of kidney disease during pregnancy classify
women primarily on the basis of their serum Cr levels.
However, the accuracy of using serum Cr level as a marker
of renal function is low due to its nonlinear association
with eGFR; that is, such association varies with age, sex,
race, and lean body mass [7]. A previous study categorized
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Table 1: Maternal characteristics and clinical characteristics stratified according to quartiles of PSP/REG I𝛼 in pregnant women.
Quartiles of PSP/REG I𝛼 I (n=148) II (n=149) III (n=149) IV (n=149) p-value
Maternal age (years) 30.96 ± 4.54 30.59 ± 4.80 30.77 ± 4.70 31.122 ± 4.85 0.781
Education (years) 14.88 ± 2.29 14.88 ± 2.70 15.336 ± 2.07 15.07 ± 2.47
0.304≤ 12
a 14(9.40) 15(10.00) 39(26.17) 41(27.52)
12–16b 122(81.88) 129(86.00) 100(67.11) 88(59.06)
> 16 13(8.72) 6(4.00) 11(7.38) 19(12.75)
Nullipara [n (%)] 67(44.97) 74(49.66) 61(40.94) 84(56.38) 0.001
Pregestational BMI (kg/m2) 21.62 ± 3.60 21.91 ± 3.01 21.21 ± 2.80 21.71 ± 3.22 0.277
Family history of
hypertension [n (%)] 11(7.38) 11(7.33) 20(13.42) 12(8.05) 0.196
Family history of diabetes
[n (%)] 8(5.37) 4(2.67) 4(2.67) 9(6.04) 0.321
Systolic BP (mmHg) 116.42 ± 10.31 116.49 ± 11.26 116.80 ± 9.58 118.32 ± 13.12 0.415
Diastolic BP (mmHg) 73.40 ± 8.80 73.07 ± 8.09 72.73 ± 7.09 74.07 ± 10.05 0.572
FBG (mmol/L) 4.54 ± 0.81 4.56 ± 0.98 4.51 ± 0.84 4.57 ± 0.98 0.936
Total Cholesterol (mmol/L) 6.42 ± 1.15 6.65 ± 1.11 6.82 ± 1.37 6.72 ± 1.37 0.163
Triglycerides (mmol/L) 4.22 ± 1.58 4.11 ± 1.53 4.32 ± 1.83 4.68 ± 2.10 0.132
LDL-cholesterol (mmol/L) 3.29 ± 0.84 3.51 ± 0.88 3.59 ± 1.10 3.51 ± 1.00 0.181
HDL-cholesterol (mmol/L) 2.06 ± 0.58 2.00 ± 0.34 2.00 ± 0.35 1.97 ± 0.38 0.585
Baseline renal parameter
UA (𝜇mol/L) 273.86 ± 64.48 287.34 ± 60.99 292.34 ± 58.81 318.52 ± 84.61 0.001
Creatinine (𝜇mol/L) 56.81 ± 8.52 58.95 ± 7.79 61.25 ± 7.35 64.91 ± 8.36 0.001
BUN (mmol/L) 3.25 ± 0.85 3.39 ± 0.95 3.34 ± 0.89 3.65 ± 0.87 0.001
eGFR (ml/min/1.73m2) 118.78 ± 17.85 116.04 ± 9.66 113.29 ± 9.85 107.99 ± 11.43 0.001
Significance, 𝑝 <0.05. Data are presented as 𝑛 (%), mean ± SD, or median (interquartile range) as appropriate. aAccepted education for 12 years means already
obtained the degree of high school. bAccepted education for 16 years means already obtained the degree of bachelor.
Table 2: Association between serum PSP/REG I𝛼 and kidney function indicator by quartiles of PSP/REG I𝛼.
I (n=148) II (n=149) III (n=149) IV (n=149)
𝑟 𝑝 𝑟 𝑝 𝑟 𝑝 𝑟 𝑝
UA 0.191 0.020 0.021 0.804 -0.095 0.247 0.100 0.224
Creatinine 0.177 0.051 -0.044 0.593 0.237 0.004 0.412 0.001
BUN 0.143 0.083 -0.090 0.276 0.162 0.048 0.059 0.478
eGFR
(ml/min/1.73m2) -0.124 0.132 0.079 0.340 -0.213 0.009 -0.355 0.001
Significance, p<0.05.
Table 3: Multiple linear regression analysis between PSP/REG I𝛼 and eGFR in pregnant women.
Variables analyzed 𝛽 SE of 𝛽 Standardized 𝛽 T p
Age 0.112 0.091 0.046 1.223 0.222
BMI -0.078 0.128 -0.023 -0.610 0.542
FBG 0.033 0.477 0.003 0.070 0.945
BUN 1.040 0.496 0.082 2.099 0.036
UA 0.022 0.007 0.134 3.338 0.001
eGFR -0.288 0.034 -0.334 -8.510 0.001
Significance, p<0.05. Abbreviations: 𝛽, regression coefficient; SE, standard error; T, One-Sample T Test; BMI, body mass index; FPG, fasting plasma glucose;
BUN, blood urea nitrogen; UA, uric acid; eGFR, estimated glomerular filtrations rate.
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CKD severity according to eGFR [20]. Although eGFR is the
most important predictor of pregnancy outcomes in women
with kidney disease, it is insensitive to mild and moderate
renal impairment. It is unlikely that any single biomarker
is perfect in the diagnosis of pregnant women’s diseases,
but detection of multiple biomarkers and statistical analysis
markedly enhance the diagnostic sensitivity and specificity.
In the present study, we found that PSP/REG I𝛼 may be a
suitable auxiliary marker of a decline in renal function in
pregnant women.
Initially, PSP and REG I𝛼 were discovered independently
in the fields of pancreatitis [21] and diabetes [22]. Sequence
analysis later revealed that PSP and REG I𝛼 are indeed iden-
tical, thus suggesting that the combined terms of PSP/REG
I𝛼 should be used in the future [23]. PSP/REG I𝛼 mRNA
is mainly detected in the pancreas, but its expression has
also been found in the gastric mucosa and the kidneys [21,
24]. The REG receptor (EXTL3) mRNA expression has also
been detected in the liver, heart, kidney, spleen, thymus,
stomach, small intestine, colon, pancreatic acinar and ductal
cells, adrenal gland, pituitary gland, testis, and brain [25–
27], suggesting the possible involvement of the REG-REG
receptor signal system in a variety of cell types other than
𝛽-cells. In our previous study, PSP/REG I𝛼 levels showed
consistent positive correlation with serum Cr and UA levels
and negative correlation with eGFR; hence, serum PSP/REG
I𝛼 levels closely reflect glomerular injury and declining renal
function in patients with type 2 diabetes [16]. All these results
support that PSP/REG I𝛼 may be associated with kidney
disease. The present study confirmed that PSP/REG I𝛼 is a
relatively a reliable and useful marker for assessment of renal
function in pregnant women.
Three mechanisms have been suggested to explain the
relationship of PSP/REG I𝛼 and kidney function. Firstly,
since PSP/REG I𝛼 is a low molecular weight protein of
16 kd, it crosses the glomerular basement membrane and
undergoes reabsorption in the proximal renal tubules [15]. A
correlation was also observed between eGFR and PSP/REG
I𝛼 levels; therefore, the increase in PSP/REG I𝛼 is more
likely to reflect reduced glomerular filtration capacity rather
than reabsorption from damaged renal tubules. Another
possible mechanism is that PSP/REG I𝛼 may be involved
in the kidney development. PSP/REG I𝛼 was first identified
in the pancreas as an anti-stone forming molecule [28, 29].
However, it also has a function as a growth factor for the
pancreas. As PSP/REG I𝛼 is predominantly expressed in the
pancreas, it may be trapped in the kidney, and the kidney
may not produce it [24]. There are reports that PSP/REG
I𝛼 has been identified in the human kidney and urine also,
which is elevated in diabetic patients [15], suggesting that
it may be involved in diabetic kidney hypertrophy as a
kidney growth factor. And finally, it has been repeatedly
shown that advanced CKD is associated with a state of
chronic inflammation, as evidenced by either elevated levels
of various proinflammatory cytokines (IL-1𝛽, IL-6, TNF-𝛼,
etc.) or altered levels of acute-phase proteins (CRP, albumin,
fetuin-A, etc.), which in turn are associated with increased
rate of CKD progression and risk of death [30, 31]. PSP/REG
I𝛼 serves as an inflammatory factor that may be involved in
CKD.
We found reliable interactions between increased
PSP/REG I𝛼 values and low eGFR. Based on Spearman’s rank
correlation analysis, PSP/REG I𝛼 levels showed consistent
positive correlations with serum Cr, BUN, and UA levels
and negative correlation with eGFR. Thus, serum PSP/REG
I𝛼 levels closely reflect glomerular injury and decline in
renal function in pregnant women. UA is predominantly
cleared by the kidneys; as such, decline in eGFR will be
almost universally associated with increased UA [32].
Hence, UA was considered primarily a marker of kidney
damage and a secondary independent risk factor for kidney
disease development and progression. Our findings on the
correlation between PSP/REG I𝛼 andUA levels further imply
that the protein is associated with kidney damage.
When we used eGFR to define mildly reduced eGFR
and normal groups, we found that participants with mildly
reduced eGFR have high PSP/REG I𝛼 levels. Moreover,
PSP/REG I𝛼 was moderately correlated with serum Cr and
eGFR only in the subgroups of quartiles III and IV. It is
reasonable that both PSP/REG I𝛼 and eGFR are at normal
levels and irrelevant when kidney function is normal. In
addition, elevated PSP/REG I𝛼 concentrations are sensitive
to renal dysfunction. Overall, PSP/REG I𝛼 is associated with
clinical kidney function impairments detected using eGFR.
To further investigate the correlation between PSP/REG I𝛼
and renal function, we conducted multivariate linear regres-
sion. eGFR, BUN, and UA remained significantly associated
with PSP/REG I𝛼 even after adjusting for age, BMI, and
FBG. This result confirms that PSP/REG I𝛼 may be a useful
epidemiological tool for evaluating mild kidney impairment
in pregnant women. However, after adjusting for serum Cr,
the association between PSP/REG I𝛼 and eGFRwas no longer
statistically significant because the CKD-EPI equation used
to estimate log GFR includes log serum Cr.
To our knowledge, this work is the first to investigate the
correlation between serum PSP/REG I𝛼 and renal function
in pregnancy.This work also conducted comprehensive mea-
surement of potentially confounding variables. However, this
study has several limitations. First, the findings are limited
to cross-sectional assessment. Further researchmust confirm
if the relationship between PSP/REG I𝛼 and eGFR is causal
or an epiphenomenon. Second, our sample size of pregnant
women with stage 3 or 4 CKD was relatively small due
to the nature of the research question. Further prospective
studies should recruit patients with different stages of CKD
to determine the potential of PSP/REG I𝛼 as a biomarker
for diagnosis and evaluation of the onset and development
of CKD in pregnant women.
5. Conclusions
In conclusion, a high PSP/REG I𝛼 level is associated with
kidney function markers, namely, eGFR and serum levels
of Cr, BUN, and UA. Our study provides clinical evidence
that serum PSP/REG I𝛼 levels may be a suitable marker for
assessment of renal function in pregnancy.
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eGFR: Estimated glomerular filtration rate
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TNF-𝛼: Tumor necrosis factor 𝛼
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Diastolic BP: Diastolic blood pressure
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